{"nctId":"NCT01572792","briefTitle":"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2012-04"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":921,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aclidinium bromide"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol Fumarate"]},{"label":"5","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)","otherNames":[]},{"name":"Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)","otherNames":[]},{"name":"Aclidinium bromide","otherNames":[]},{"name":"Formoterol Fumarate","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of the treatment phase of the lead-in study, LAC-MD-31\n* Written informed consent obtained from the patient before the initiation of any study specific procedures\n* No medical contraindication as judged by the PI\n* Compliance with LAC-MD-31 study procedures and IP dosing.\n\nExclusion Criteria:\n\n* No specific exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients to Experience Any Treatment-emergent Adverse Event","description":"For each safety parameter, the last assessment made before the first dose of investigational product in the lead-in study (LAC MD-31) was used as the baseline for all analyses of that safety parameter in this extension study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"65.9","spread":null},{"groupId":"OG002","value":"61.3","spread":null},{"groupId":"OG003","value":"67.5","spread":null},{"groupId":"OG004","value":"64.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Clinical Laboratory Values for Hematology, Chemistry or Urinalysis","description":"Potentially clinically significant change:\n\n\\>1.15 × upper limit of normal (ULN) for absolute cell count of basophils, eosinophils or monocytes, blood alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total bilirubin, blood urea nitrogen, total cholesterol, creatine kinase, creatinine, gamma glutamyl transferase, lactate dehydrogenase, triglycerides or uric acid \\<0.85 x lower limit of normal (LLN) or \\> 1.15 ULN for hematocrit ratio, haemoglobin, lymphocytes or neutrophils absolute cell count, platelet count (thrombocytes), red or white blood cell count, calcium, fasting glucose, phosphorus, total protein, or urinary pH \\<0.95 x LLN or \\>1.05 x ULN for chloride, potassium, sodium Urinary glucose ≥0.015, blood or ketones or protein ≥1 or specific gravity \\>1.1 × ULN\n\nThe last assessment made before the first dose of investigational product in the lead-in study was used as the baseline for all safety analyses in the extension study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"41.2","spread":null},{"groupId":"OG002","value":"35.3","spread":null},{"groupId":"OG003","value":"32.5","spread":null},{"groupId":"OG004","value":"38.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients to Experience a Potentially Significant Post-baseline 12-lead ECG Value","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"55.9","spread":null},{"groupId":"OG003","value":"60.4","spread":null},{"groupId":"OG004","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"2.9","spread":null},{"groupId":"OG003","value":"2.6","spread":null},{"groupId":"OG004","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"37.0","spread":null},{"groupId":"OG002","value":"39.7","spread":null},{"groupId":"OG003","value":"35.6","spread":null},{"groupId":"OG004","value":"38.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"8.3","spread":null},{"groupId":"OG002","value":"9.8","spread":null},{"groupId":"OG003","value":"5.7","spread":null},{"groupId":"OG004","value":"8.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"28.7","spread":null},{"groupId":"OG002","value":"30.4","spread":null},{"groupId":"OG003","value":"27.8","spread":null},{"groupId":"OG004","value":"30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"0.5","spread":null},{"groupId":"OG004","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"6.6","spread":null},{"groupId":"OG002","value":"3.9","spread":null},{"groupId":"OG003","value":"2.6","spread":null},{"groupId":"OG004","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"3.1","spread":null},{"groupId":"OG004","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null},{"groupId":"OG004","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"6.0","spread":null},{"groupId":"OG002","value":"8.3","spread":null},{"groupId":"OG003","value":"7.2","spread":null},{"groupId":"OG004","value":"4.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.086","spread":"0.017"},{"groupId":"OG001","value":"0.198","spread":"0.015"},{"groupId":"OG002","value":"0.166","spread":"0.015"},{"groupId":"OG003","value":"0.112","spread":"0.015"},{"groupId":"OG004","value":"0.109","spread":"0.015"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Morning Predose (Trough) Forced Expiratory Volume in One Second (FEV1)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.101","spread":"0.017"},{"groupId":"OG001","value":"0.038","spread":"0.015"},{"groupId":"OG002","value":"0.005","spread":"0.015"},{"groupId":"OG003","value":"0.030","spread":"0.015"},{"groupId":"OG004","value":"0.004","spread":"0.015"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Transition Dyspnea Index (TDI) Focal Score at End of Study","description":"The TDI measures the change from baseline in severity of breathlessness in symptomatic patients. The TDI contains a rating for 3 categories (functional impairment, magnitude of task, magnitude of effort). TDI scale ranges from -3 (major deterioration) to +3 (major improvement) including a 0 score to indicate \"no change\". The 3 categories are added to obtain a focal score ranging from -9 (including 0) to +9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.731","spread":"0.277"},{"groupId":"OG001","value":"1.812","spread":"0.251"},{"groupId":"OG002","value":"1.742","spread":"0.235"},{"groupId":"OG003","value":"1.596","spread":"0.241"},{"groupId":"OG004","value":"1.324","spread":"0.246"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score","description":"St George's Respiratory Questionnaire (SGRQ) measures COPD-specific health outcomes and consists of 3 dimension scores (symptom, activity and impact). SGRQ total score is the sum of these scores and ranges from 0 (best health status) to 100 (worst health status).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.862","spread":"0.945"},{"groupId":"OG001","value":"-3.646","spread":"0.861"},{"groupId":"OG002","value":"-5.527","spread":"0.819"},{"groupId":"OG003","value":"-4.306","spread":"0.847"},{"groupId":"OG004","value":"-4.059","spread":"0.853"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Vital Signs (Pulse Rate, Systolic or Diastolic Blood Pressure or Weight)","description":"Potentially clinically significant change:\n\nSystolic BP ≥180 mmHg and increase ≥20 mmHg from baseline or ≤90 mmHg and decrease ≥20 mmHg from baseline Diastolic BP ≥105 mmHg and increase ≥15 mmHg from baseline or ≤50 mmHg and decrease ≥15 mmHg from baseline Pulse rate ≥110 bpm and increase ≥15% from baseline or ≤50 bpm and decrease ≥15% from baseline Weight increase or decrease ≥7% from baseline\n\nThe last assessment made before the first dose of investigational product in the lead-in study was used as the baseline for all safety analyses in the extension study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"24.2","spread":null},{"groupId":"OG002","value":"18.6","spread":null},{"groupId":"OG003","value":"22.2","spread":null},{"groupId":"OG004","value":"24.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":146},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Cough"]}}}